Quick Answer
Marker Therapeutics, Inc. reported Cash and Equivalents of $16.07 million for fiscal year 2025.
Marker Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $16.07M | -16.3% |
| 2024 | $19.19M | +27.0% |
| 2023 | $15.11M | +28.3% |
| 2022 | $11.78M | -72.2% |
| 2021 | $42.35M | +98.3% |
| 2020 | $21.35M | -51.4% |
| 2019 | $43.90M | -28.9% |
| 2018 | $61.75M | +1103.8% |
| 2017 | $5.13M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.59M | +95.5% | +68.1% |
| June 30, 2025 | $10.46M | +34.1% | -23.6% |
| March 31, 2025 | $13.69M | +20.9% | -28.7% |
| December 31, 2024 | $19.19M | +27.0% | +113.3% |
| September 30, 2024 | $9.00M | -48.5% | +15.4% |
| June 30, 2024 | $7.80M | -57.0% | -31.1% |
| March 31, 2024 | $11.32M | +76.9% | -25.1% |
| December 31, 2023 | $15.11M | +28.3% | -13.5% |
- Marker Therapeutics, Inc. showed a decrease of -16.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2025 period, Marker Therapeutics, Inc.’s cash and equivalents has grown by 213.3% (from $5.13 million to $16.07 million).
- The most recent figure is from Marker Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: